Please wait while the formulary information is being retrieved.
Drug overview for ZERVIATE (cetirizine hcl):
Generic name: cetirizine HCl (se-TIR-i-zeen)
Drug class: Ophthalmic Antiallergic Agents
Therapeutic class: Ophthalmic Agents
Cetirizine hydrochloride is a histamine H1-receptor antagonist.
No enhanced Uses information available for this drug.
Generic name: cetirizine HCl (se-TIR-i-zeen)
Drug class: Ophthalmic Antiallergic Agents
Therapeutic class: Ophthalmic Agents
Cetirizine hydrochloride is a histamine H1-receptor antagonist.
No enhanced Uses information available for this drug.
DRUG IMAGES
- ZERVIATE 0.24% EYE DROP
The following indications for ZERVIATE (cetirizine hcl) have been approved by the FDA:
Indications:
Allergic conjunctivitis
Professional Synonyms:
Allergy eye itch
Atopic conjunctivitis
Itchy eyes due to allergies
Ocular itching due to allergies
Indications:
Allergic conjunctivitis
Professional Synonyms:
Allergy eye itch
Atopic conjunctivitis
Itchy eyes due to allergies
Ocular itching due to allergies
The following dosing information is available for ZERVIATE (cetirizine hcl):
It isessential that the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
No enhanced Administration information available for this drug.
DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
---|---|---|
ZERVIATE 0.24% EYE DROP | Maintenance | Adults instill 1 drop into affected eye(s) by ophthalmic route 2 times per day |
No generic dosing information available.
The following drug interaction information is available for ZERVIATE (cetirizine hcl):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for ZERVIATE (cetirizine hcl):
Drug contraindication overview.
None.
None.
There are 0 contraindications.
There are 0 severe contraindications.
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
Moderate List |
---|
No disease contraindications |
The following adverse reaction information is available for ZERVIATE (cetirizine hcl):
Adverse reaction overview.
The most common adverse reactions (1-7%) were ocular hyperemia, instillation site pain, and visual acuity reduced.
The most common adverse reactions (1-7%) were ocular hyperemia, instillation site pain, and visual acuity reduced.
There are 0 severe adverse reactions.
There are 4 less severe adverse reactions.
More Frequent | Less Frequent |
---|---|
Ocular pain Ocular redness Reduced visual acuity |
None. |
Rare/Very Rare |
---|
Anticholinergic toxicity |
The following precautions are available for ZERVIATE (cetirizine hcl):
The safety and effectiveness of cetirizine hydrochloride has been established in pediatric patients two years of age and older. Use of cetirizine hydrochloride in these pediatric patients is supported by evidence from adequate and well-controlled studies of cetirizine hydrochloride in pediatric and adult patients.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
None |
Severe Precaution
None |
Management or Monitoring Precaution
None |
Risk Summary: There were no adequate or well-controlled studies with cetirizine hydrochloride ophthalmic solution (cetirizine 0.24%) in pregnant women. Cetirizine should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal Data: Cetirizine was not teratogenic in mice, rats, or rabbits at oral doses up to 96, 225, and 135 mg/kg, respectively (approximately 1300, 4930, and 7400 times the maximum recommended human ophthalmic dose, on a mg/m 2 basis).
Cetirizine has been reported to be excreted in human breast milk following oral administration. Multiple doses of oral cetirizine (10 mg tablets once daily for 10 days) resulted in systemic levels (mean C max= 311 ng/mL) that were 100 times higher than the observed human exposure (mean C max= 3.1 ng/mL) following twice-daily administration of cetirizine ophthalmic solution 0.24% to both eyes for one week.
Comparable bioavailability has been found between the tablet and syrup dosage forms. However, it is not known whether the systemic absorption resulting from topical ocular administration of cetirizine hydrochloride could produce detectable quantities in human breast milk. There is no adequate information regarding the effects of cetirizine on breastfed infants, or the effects on milk production to inform risk of cetirizine hydrochloride to an infant during lactation. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for cetirizine hydrochloride and any potential adverse effects on the breastfed child from cetirizine hydrochloride.
Comparable bioavailability has been found between the tablet and syrup dosage forms. However, it is not known whether the systemic absorption resulting from topical ocular administration of cetirizine hydrochloride could produce detectable quantities in human breast milk. There is no adequate information regarding the effects of cetirizine on breastfed infants, or the effects on milk production to inform risk of cetirizine hydrochloride to an infant during lactation. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for cetirizine hydrochloride and any potential adverse effects on the breastfed child from cetirizine hydrochloride.
No overall differences in safety or effectiveness have been observed between elderly and younger patients.
The following prioritized warning is available for ZERVIATE (cetirizine hcl):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for ZERVIATE (cetirizine hcl)'s list of indications:
Allergic conjunctivitis | |
H10.1 | Acute atopic conjunctivitis |
H10.10 | Acute atopic conjunctivitis, unspecified eye |
H10.11 | Acute atopic conjunctivitis, right eye |
H10.12 | Acute atopic conjunctivitis, left eye |
H10.13 | Acute atopic conjunctivitis, bilateral |
H10.44 | Vernal conjunctivitis |
H10.45 | Other chronic allergic conjunctivitis |
H16.26 | Vernal keratoconjunctivitis, with limbar and corneal involvement |
H16.261 | Vernal keratoconjunctivitis, with limbar and corneal involvement, right eye |
H16.262 | Vernal keratoconjunctivitis, with limbar and corneal involvement, left eye |
H16.263 | Vernal keratoconjunctivitis, with limbar and corneal involvement, bilateral |
H16.269 | Vernal keratoconjunctivitis, with limbar and corneal involvement, unspecified eye |
Formulary Reference Tool